Design Therapeutics, Inc.
DSGN
$15.62
-$0.17-1.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 7.11% | -7.98% | |||
| Gross Profit | -7.11% | 7.98% | |||
| SG&A Expenses | 12.29% | 0.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.46% | -5.91% | |||
| Operating Income | -8.46% | 5.91% | |||
| Income Before Tax | -10.25% | 5.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.25% | 5.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.25% | 5.88% | |||
| EBIT | -8.46% | 5.91% | |||
| EBITDA | -8.53% | 5.97% | |||
| EPS Basic | -5.40% | 8.71% | |||
| Normalized Basic EPS | -5.41% | 8.74% | |||
| EPS Diluted | -5.40% | 8.71% | |||
| Normalized Diluted EPS | -5.41% | 8.74% | |||
| Average Basic Shares Outstanding | 4.60% | 3.13% | |||
| Average Diluted Shares Outstanding | 4.60% | 3.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||